Search clinical trials for: Relapsed and/or Refractory

Total 10103 results

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
BGI, China
Shenzhen University General Hospital

Recruiting

Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T (GI-hNeoT-01)

T-cell Lymphoma

China
Uma Borate

Recruiting

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 Mutation

United States
Hangzhou GluBio Pharmaceutical Co., Ltd.

Recruiting

A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

Non-Hodgkin Lymphoma

China
Pfizer
Bristol-Myers Squibb

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Multiple Myeloma

United States, Canada
M.D. Anderson Cancer Center
Genentech, Inc.; Kite, A Gilead Company

Recruiting

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

B Cell Lymphoma

United States
Institute of Hematology & Blood Diseases Hospital...
Suzhou Fundamenta Therapeutics

Recruiting

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

Autoimmune Hemolytic Anemia | CD19 CAR-T Cell Infusion

China
920th Hospital of Joint Logistics Support Force...
Shanghai PerHum Therapeutics Co., Ltd.

Recruiting

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

Lymphoma, B-Cell | CAR-T

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Chi-GVM Regimen for the Treatment of R/R PTCL

Relapsed/Refractory Peripheral T-cell Lymphoma

China
British Columbia Cancer Agency

Not yet recruiting

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

B-cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Leukemia | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | High-grade B-cell Lymphoma

Canada
Janssen Research & Development, LLC

Recruiting

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide (MonumenTAL-6)

Relapsed or Refractory Multiple Myeloma

Germany, Korea, Republic of, Italy, France, Japan, Israel, Belgium, Denmark, Sweden, China, Spain, Czechia, Poland, Australia, Netherlands, Argentina, Canada, United Kingdom, Greece, Brazil, India
Beijing Immunochina Medical Science & Technology...
Peking University People's Hospital

Not yet recruiting

INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia

Leukemia, B-cell
Shanghai Simnova Biotechnology Co.,Ltd.
Wuhan Union Hospital, China

Recruiting

F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

China
University of Chicago

Not yet recruiting

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Lymphoblastic Lymphoma | Acute Leukemia | Lymphoblastic Leukemia

United States
Elvira Umyarova
Sanofi

Recruiting

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Recurrent Multiple Myeloma

United States
Huda Salman

Recruiting

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

Acute Myeloid Leukemia

United States
Xuzhou Medical University

Recruiting

Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)

Multiple Myeloma

China
Navy General Hospital, Beijing

Recruiting

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Refractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin Lymphoma

China
Mayo Clinic

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Ryvu Therapeutics SA

Recruiting

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Acute Myeloid Leukemia

Italy, Poland
Curon Biopharmaceutical (Shanghai) Co.,Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

China
Chongqing Precision Biotech Co., Ltd
Peking University Cancer Hospital & Institute

Recruiting

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

B Cell Lymphoma | Non Hodgkin Lymphoma

China
Beijing Yongtai Ruike Biotechnology Company Ltd

Recruiting

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia

China
St. Jude Children's Research Hospital
Syndax Pharmaceuticals

Recruiting

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Refractory Acute Myeloid Leukemia | Acute Leukemia of Ambiguous Lineage | Relapsed Acute Myeloid Leukemia

United States
Navy General Hospital, Beijing
Chinese PLA General Hospital

Recruiting

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Angioimmunoblastic T Cell Lymphoma

Relapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell Lymphoma

China
Autolus Limited

Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United Kingdom
BeBetter Med Inc

Recruiting

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

China
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Relapsed or Refractory Multiple Myeloma

Taiwan
National Cancer Centre, Singapore
Merck Sharp & Dohme LLC; National Medical Research Council (NMRC), Singapore

Not yet recruiting

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma (POLAR)

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

Singapore
The First Affiliated Hospital of Xiamen University
The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaborators

Recruiting

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Follicular Lymphoma | Relapsed Non-Hodgkin Lymphoma | Refractory B-Cell Lymphoma

China
AbbVie

Recruiting

Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Israel, Taiwan
The First Affiliated Hospital of Xiamen University

Recruiting

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

China
Children's Hospital of Philadelphia
Children's Hospital Colorado; Exelixis; Alex's Lemonade Stand Foundation

Recruiting

Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma

Osteosarcoma | Ewing Sarcoma

United States
University Hospital Tuebingen

Recruiting

Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML (VenSwitch)

AML | MDS

Germany
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

United States, France, Spain, Germany
Pfizer

Recruiting

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Multiple Myeloma

Japan, United States, Canada
The First Affiliated Hospital of Xiamen University
The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaborators

Recruiting

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Peripheral T Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma | Refractory T-Cell Lymphoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Single Arm Clinical Study on the Safety and Efficacy of Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

Refractory Solid Tumors | Relapsed Solid Tumors

China
Ever Supreme Bio Technology Co., Ltd.

Not yet recruiting

A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors (CAR001)

Solid Tumor

Taiwan
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

Lymphoma, Non-Hodgkin | Diffuse Large B Cell Lymphoma

China
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

Relapsed/Refractory Follicular Lymphoma | Marginal Zone Lymphoma (MZL)

Korea, Republic of, Australia, France, Spain, Malaysia, Taiwan, Italy, Poland, United States, Turkey, Thailand, United Kingdom, Belgium, Czechia
GluBio Therapeutics Inc.

Recruiting

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Massachusetts General Hospital
Pfizer

Recruiting

Elranatamab in R/R Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

United States
AstraZeneca

Recruiting

AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. (PRIMAVERA)

Lymphoma | Hodgkin Lymphoma | Non-Hodgkin

Australia, Korea, Republic of, United Kingdom, Italy, Germany, France, United States, Spain
ETH Zurich
University of Zurich

Not yet recruiting

Pharmacoscopy-guided Clinical Standard-of-care in r/r AML (RAPID-01)

AML, Adult
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

T-lymphoblastic Lymphoma | T-ALL

China
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML

Acute Myeloid Leukemia
Xuzhou Medical University
Yake Biotechnology Ltd.

Recruiting

Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma (CAR-T)

Multiple Myeloma

China
Lantern Pharma Inc.

Recruiting

A Study of LP-284 in Relapsed or Refractory Lymphomas and Solid Tumors

Advanced Solid Tumor | Relapsed or Refractory Lymphomas

United States
Children's Hospital Medical Center, Cincinnati

Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Lymphoma | Follicular Lymphoma | Leukemia | B Cell Lymphoma | Hodgkin Lymphoma | Burkitt Lymphoma | AML | Non Hodgkin Lymphoma | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Diffuse Large B Cell Lymphoma | Hematologic Malignancy | Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm | T-cell Lymphoma | Peripheral T Cell Lymphoma and other conditions

United States

Search clinical trials for: Relapsed and/or Refractory

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations